Jyong Biotech Ltd. Stock Price, News & Analysis

Jyong Biotech (Nasdaq: MENS), a Taiwan-based biotechnology company focused on plant-derived drugs for urinary system diseases, announced its Chairwoman and CEO Fu Feng Kuo will speak at The 2025 Global Business Forum on September 19, 2025.

The event, held at the Taipei International Convention Center, is organized by the Taiwanese Chambers of Commerce of North America in partnership with U.S. venture capital and biotech industry representatives. The forum will focus on three key themes: innovative drug technology development, cross-border clinical collaboration, and strategic capital deployment.

Jyong Biotech (NASDAQ:MENS) has announced the completion of patient enrollment in its Phase II clinical trial for MCS-8, a plant-derived investigational drug candidate for prostate cancer prevention. The trial has successfully enrolled over 700 high-risk subjects across 20 hospitals in Taiwan, involving more than 130 urologists.

The study is designed as a randomized, placebo-controlled trial. Despite COVID-19 challenges, the company has achieved this milestone ahead of schedule. The company plans to analyze the trial data after completing the treatment period and will disclose results according to applicable requirements.

Jyong Biotech (NASDAQ:MENS) presented clinical trial results at the 22nd Urological Association of Asia Congress for two key drug candidates. The company's Phase III trials for BOTRESO®, targeting benign prostatic hyperplasia (BPH), showed significant improvement in lower urinary tract symptoms for Asian and pooled Taiwan-U.S. populations, though U.S. subgroup results were not significant. The 52-week extension studies demonstrated consistent long-term improvement with no serious adverse events.

Additionally, their Phase II trial for MCS-8 (PCP) met primary efficacy endpoints, showing lower rates of positive prostate biopsies and high-grade prostate cancer compared to placebo after 104 weeks. The global BPH market is projected to reach $9.8 billion by 2026, up from $4.1 billion in 2020. Jyong Biotech maintains global patent coverage and is pursuing international partnerships for market entry.

Jyong Biotech (NASDAQ:MENS), a Taiwan-based biotechnology company, marked two significant milestones: its Nasdaq IPO bell ringing ceremony on July 2, 2025, and participation in the BIO 2025 International Convention from June 16-19 in Boston.

The company showcased its flagship product MCS®-2, targeting the benign prostatic hyperplasia (BPH) market, which is projected to grow from $4.1 billion in 2020 to $9.8 billion by 2026. Jyong Biotech specializes in plant-derived drugs for urinary system diseases, focusing on the U.S., EU, and Asian markets.

The company plans to expand MCS®-2's market penetration through regional licensing partnerships while pursuing research and development in the urology sector.

Jyong Biotech Ltd. (NASDAQ: MENS), a Taiwan-based biotechnology company focused on plant-derived drugs for urinary system diseases, has successfully completed its Initial Public Offering (IPO) on June 18, 2025. The company raised $20 million by offering 2,666,667 ordinary shares at $7.5 per share on the Nasdaq Global Market. The underwriters have a 45-day option to purchase up to 400,000 additional shares. The proceeds will be allocated to fund Phase III trials of MCS-2 (40%), earlier phase trials (25%), Phase II trial of PCP (10%), Phase I trial of IC (5%), and general corporate purposes (20%). Joseph Stone Capital, LLC served as the sole underwriter for this firm commitment offering.

Jyong Biotech Ltd., a Taiwan-based biotechnology company focused on plant-derived drugs for urinary system diseases, has announced the pricing of its IPO on the Nasdaq Global Market under the symbol MENS. The company is offering 2,666,667 ordinary shares at $7.50 per share, aiming to raise $20 million in gross proceeds. Trading will commence on June 17, 2025, with an additional over-allotment option of 400,000 shares. The proceeds will primarily fund Phase III trials of MCS-2 (40%), earlier phase trials (25%), Phase II trial of PCP (10%), Phase I trial of IC (5%), and general corporate purposes (20%). Joseph Stone Capital is serving as the sole underwriter for this firm commitment offering.